Company: APXIF
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026189
Chunk: 427

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1A
Chunk 427
---
 Company Material Adverse Effect or, if the MultiplAI
SPA has not been terminated in accordance with its terms, any MultiplAI Material Adverse Effect; (f) if the MultiplAI SPA has not been
terminated in accordance with its terms, the consummation of the MultiplAI Contribution; and (g) OmnigenicsAI having, immediately prior
to the Merger Effective Time, (i) no more than 34,000,000 issued and outstanding Company Shares (on a fully diluted basis after consummation
of the Restructuring and the MultiplAI Contribution) in addition to any Company Shares issued pursuant to any PIPE Subscription Agreements
and the Backstop Agreement; or (ii) if the transactions under the MultiplAI SPA are not consummated and the MultiplAI SPA is terminated,
no more than 30,000,000 issued and outstanding Company Shares (on a fully diluted after consummation of the Restructuring), in addition
to any Company Shares issued pursuant to any PIPE Subscription Agreements and the Backstop Agreement.

The obligations of OmnigenicsAI and Merger Sub
to consummate the Proposed Business Combination are subject to certain additional conditions at or prior to the Closing, including (a)
the accuracy of certain representations and warranties of the Company except, with respect to certain representations and warranties,
where the failure of such representations and warranties to be true and correct does not result in a SPAC Material Adverse Effect; (b)
the performance or compliance in all material respects with all agreements and covenants required by the Proposed Business Combination
Agreement; and (c) the absence of a SPAC Material Adverse Effect.

While the obligation of MultiplAI to consummate
the Proposed Business Combination is subject to the consummation of the transactions contemplated by the MultiplAI SPA, the obligations
of the parties to the Business Combination Agreement (other than MultiplAI) to consummate the Proposed Business Combination is not subject
to the consummation of the transactions contemplated by the MultiplAI SPA.

Representations and Warranties 

The Business Combination Agreement contains customary
representations and warranties of the Company, OmnigenicsAI and Merger Sub relating to, among other things, their ability to enter into
the Business Combination Agreement and the other Transaction Documents to which they are party and their outstanding capitalization. The
representations and warranties of the parties contained in the Business Combination Agreement will terminate and be of no further force
and